PL Marketing IncOvernight Travel Reset Merchandiser PL Marketing IncOvernight Travel Reset Merchandisermemphis, TNDecision Making \u2013 identifying and understanding issues, problems and opportunities; comparing data from different sources to draw conclusions; using effective approaches for choosing a course of action or developing appropriate solutions; taking action that is consistent with available facts, constraints and probable consequences. Inclusion \u2013 appreciating and leveraging the capabilities, insights and ideas of all individuals; working effectively with individuals of diverse style, ability and motivation for a direct effect on business results.
Mississippi Land BankMarketing Intern Mississippi Land BankMarketing InternSenatobia, MississippiMississippi Land Bank is dedicated to fostering an engaged workplace that makes every employee feel valued, appreciated, and heard. If you are interested in being a part of a growing company that values its employees, develops talent, and has a passion for impacting the agricultural world then we would love to speak with you!
Taylor Strategy PartnersNewSpecialty Sales Representative - Cardiometabolic Rare Disease Taylor Strategy PartnersSpecialty Sales Representative - Cardiometabolic Rare DiseaseMemphis, TNRemote$160,000–$180,000 / yearThis is a unique opportunity to play a meaningful role in the launch and growth of our cardiometabolic portfolio, including Plozasiran (siRNA targeting APOC3), developed for patients with rare and high-need cardiovascular conditions such as Familial Chylomicronemia Syndrome (FCS) and Severe Hypertriglyceridemia (SHTG). Arrowhead is leading the field in bringing the promise of RNAi to address diseases outside of the liver, and our clinical pipeline includes disease targets in the liver and lung with a promising pipeline of preclinical candidates.
Taylor Strategy PartnersSpecialty Sales Representative – Cardiometabolic Rare Disease Taylor Strategy PartnersSpecialty Sales Representative – Cardiometabolic Rare DiseaseMemphis, TNRemote$160,000–$180,000 / yearThis is a unique opportunity to play a meaningful role in the launch and growth of our cardiometabolic portfolio, including Plozasiran (siRNA targeting APOC3), developed for patients with rare and high-need cardiovascular conditions such as Familial Chylomicronemia Syndrome (FCS) and Severe Hypertriglyceridemia (SHTG). Arrowhead is leading the field in bringing the promise of RNAi to address diseases outside of the liver, and our clinical pipeline includes disease targets in the liver and lung with a promising pipeline of preclinical candidates.